Agreement expands Quintiles features to aid drug approvals in Japan Quintiles Transnational Corp.

South Africa has the highest burden of HIV worldwide and a quickly expanding MDR-TB epidemic. In April, Einstein researchers had been awarded a five-year, $3.9 million grant from the NIAID to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. ‘The findings could alter public health approaches for managing the XDR-TB epidemic in the developing world,’ said principal investigator Sarita Shah, M.D., M.P.H., assistant professor of medication and of epidemiology & population health. In May, James Brust, M.D., assistant professor of medicine, received a five-year, $665,000 NIAID Career Development Award to judge a novel, home-based cure he developed for sufferers co-infected with MDR-TB and HIV in rural South Africa. Until recently, MDR-TB was treated at centralized TB referral hospitals, with sufferers admitted for half a year of treatment.Among the industry’s leading imaging CROs, ACR Image Metrix specializes in offering imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.

ARIAD reports $47.8 million net loss for second quarter 2011 ARIAD Pharmaceuticals, Inc. today reported monetary results for the next quarter and half a year ended June 30, 2010 and provided an upgrade on corporate advancements. Berger, M.D., chairman and ceo of ARIAD. ‘Individual enrollment in the pivotal PACE trial of ponatinib is usually closing, and interim data will be presented this year later. Our partner, Merck, offers filed for regulatory approval of ridaforolimus with the European Medicines Agency in europe, and we expect Merck to post a new drug software in the U.S.